iiinova — where your digital self keeps evolving

Peter Maybarduk @maybarduk.bsky.social · 26/09/2026

Because Trump so respects weakness.

Peter Maybarduk @maybarduk.bsky.social · 19/09/2026

We are fighting the redactions in court and still pushing for more documents and disclosures. These FOIA'd documents at least show us the structure of the agreements, in significant part. Read the texts for yourself here: www.citizen.org/article/foia... Thanks @sarahkarlin-smith.bsky.social

citizen.org

FOIA Documents: Trump-Pharma MFN Drug Pricing Deals - Public Citizen

The Trump administration has signed dozens of “most favored nation” (MFN) agreements with pharmaceutical companies, claiming to provide Americans with…

1205

Peter Maybarduk @maybarduk.bsky.social · 19/09/2026

For some sections of the MFN deals, even the headers are redacted. Trump's HHS won't even tell the American people what it's not telling them. Rules affecting meds access typically are made in public, through legislation or process with public comment. Not Trump's deals. What's being traded here?

12411

Peter Maybarduk @maybarduk.bsky.social · 19/09/2026

Some drugmakers say they will stop selling new drugs to key countries, in order to keep the most-favored nation price high in the United States. That could mean patients with no route to access. Here, HHS appears to bless that deadly practice:

2216

Peter Maybarduk @maybarduk.bsky.social · 19/09/2026

Trump claims lower GLP-1 prices from his deals. But Lilly’s deal contains a loophole that insulates it from providing a true MFN price point for its GLP-1 drugs. If the loophole is applied to all GLP-1 drugs, it could cost Medicaid $1.7 billion in savings. Analysis: www.citizen.org/article/publ...

citizen.org

Public Citizen FOIA Reveals That Pharma, Not Patients Are Favored In Trump’s Drug Pricing Deals - Public Citizen

Key Takeaways Copies of Pfizer and Eli Lilly’s “most-favored nation” (MFN) agreements obtained by Public Citizen through the Freedom of…

13412

Peter Maybarduk @maybarduk.bsky.social · 19/09/2026

We obtained Trump’s confidential drug pricing deals with Pfizer & Lilly via FOIA litigation. The texts are heavily redacted, making it impossible to verify some of Trump's claims. But unredacted text shows Trump exaggerated his drug pricing achievements, which expire anyway at the end of his term.

112863

Peter Maybarduk @maybarduk.bsky.social · 09/06/2026

“Access requirements are now spreading among research funders, who are convening to discuss how to coordinate their policies to grantees … “Access provisions will spread more rapidly if they are public … & can then act as a baseline from which funders can collectively raise their requirements."

000

Peter Maybarduk @maybarduk.bsky.social · 09/06/2026

“We encourage CEPI to strengthen & disclose terms relevant for equity, including licensing, step-in rights, supply, price; to adopt broader formal LMIC and civil-society participation in oversight … and to support systematically regional manufacturing ecosystems.

110

Peter Maybarduk @maybarduk.bsky.social · 09/06/2026

"CEPI indicates that it is reviewing its access policy and exploring greater transparency as it prepares to implement its new strategy. The question remains whether any changes will be incremental or norm-setting.

100

Peter Maybarduk @maybarduk.bsky.social · 09/06/2026

www.thelancet.com/journals/lan... Reluctance to publish contract terms has reduced health funding accountability. “Despite long-standing stakeholder concerns related to insufficient transparency, CEPI's underlying approach has not substantively changed …

thelancet.com

How CEPI can enhance global vaccine equity and transparency

The absence of proven vaccines to address the 2026 outbreaks of hantavirus and Ebola virus disease caused by Bundibugyo virus (species Orthoebolavirus bundibugyoense) underscores the essential role of...

110

Peter Maybarduk @maybarduk.bsky.social · 09/06/2026

Vax investment should be transparent, especially access terms. CEPI committed $50m to Moderna for Ebola, but has not published the terms. CEPI “should be judged above all by its access mission, because that is what distinguishes it from a conventional innovation fund.” Our comment in The Lancet:

101

Peter Maybarduk @maybarduk.bsky.social · 04/06/2026

We also are working with African & global experts to support countries speaking up about unfair terms. Countries need these health agreements after the cuts. But that doesn't mean we accept the Trump’s extractivism or efforts to divide and conquer the partners of the United States.

000

Peter Maybarduk @maybarduk.bsky.social · 04/06/2026

"… The Trump administration has kept details of the proposed agreements—and even signed accords—secret, although some apparent drafts have circulated online.”

100

Peter Maybarduk @maybarduk.bsky.social · 04/06/2026

“Zimbabwe, Ghana & Zambia have said no or dragged out negotiations over the Trump administration’s self-described America First foreign-assistance policies, which aim to tie health aid more directly to U.S. diplomatic and security goals.

100

Peter Maybarduk @maybarduk.bsky.social · 04/06/2026

We spoke with WSJ for this excellent piece about African states pushing back against Trump’s extractive deals. "Public Citizen, a Washington-based consumer group, has sued the State Department in an effort to force release of the details. The federal suit is pending.” www.wsj.com/world/africa...

wsj.com

Trump Wants Minerals, Health Data for Aid. African Nations Are Pushing Back.

Governments bridle at U.S. demands for private medical data and, in some cases, access to minerals.

100

Peter Maybarduk @maybarduk.bsky.social · 31/03/2026

Where Gilead fails to make its patented drug readily available and affordable, countries can overcome the patent barrier with compulsory licenses that authorize generic competition. We will encourage countries to act.

010

Peter Maybarduk @maybarduk.bsky.social · 31/03/2026

Refusing to make medicine available to Doctors Without Borders is cartoon villainy, but many lives are at stake, and no one is laughing.

120

Peter Maybarduk @maybarduk.bsky.social · 31/03/2026

Access to lenacapavir could help end AIDS, but not without much more ambition. An obvious first step is ensuring that medical humanitarian missions have all the supply they need to curb transmission and save lives.

110

Peter Maybarduk @maybarduk.bsky.social · 31/03/2026

Gilead’s reported refusal to sell lenacapavir to MSF is hard to understand and impossible to justify, apart from Gilead’s wish to sell more to rich countries at high prices.

110

Peter Maybarduk @maybarduk.bsky.social · 31/03/2026

Gilead spends a lot of money cultivating an image of allyship with communities affected by HIV. It’s very hard to take that image seriously today.

110

Peter Maybarduk @maybarduk.bsky.social · 30/03/2026

Where Gilead fails to make its patented drug available, countries have clear cause to overcome the patent monopoly with compulsory licenses that authorize generic competition. We will encourage countries to act.

000

Reposted by Peter Maybarduk

Sarah Karlin-Smith @sarahkarlin-smith.bsky.social · 20/03/2026

CNN article: Medicare is a brighter spot, expanding coverage for some patients as part of the November deal, but still doesn’t cover weight-loss drugs for all who might want them. www.cnn.com/2026/03/19/h... Reality: Not clear this Medicare program can even get off the ground!

citizen.org

Off-BALANCE? Trump’s Obesity Drug Demo May Not Live Up To The Hype - Public Citizen

What is the BALANCE Model? On December 23, 2025, the Center for Medicare and Medicaid Innovation Center announced the BALANCE…

062

Reposted by Peter Maybarduk

Public Citizen @publiccitizen.bsky.social · 10/03/2026

Get a load of this S#$%: Pfizer's CEO said European nations must pay even more for medicines or risk losing their supply. Does he want to hold drugs hostage at the expense of human lives to make a little more money? Pfizer must end this threat & take accountability for its high drug prices!

33514

Peter Maybarduk @maybarduk.bsky.social · 10/03/2026

Pfizer’s CEO said Pharma may “stop supplying” countries that don’t pay more in response to Trump’s threats & pressure campaign. This would be a classic “working failure,” grounds for compulsory license in every patent law. Drugmakers that threaten supply lose monopoly privileges. We wrote Bourla:

121

Peter Maybarduk @maybarduk.bsky.social · 04/03/2026

Thank you, on behalf of my patience and my kid’s need for me to get fewer damn texts

000

Peter Maybarduk @maybarduk.bsky.social · 04/03/2026

Key reading for knowing how and why things are moving in global health

012

Peter Maybarduk @maybarduk.bsky.social · 25/02/2026

The White House still has not published any of its deals with drugmakers, making its claims to have lowered prices very difficult to believe. But we know for a fact Trump & GOP gave pharma an $8+ billion payout out of pockets of taxpayers & cancer patients via the Big Ugly Bill.

citizen.org

Don’t Buy Trump’s SOTU Claims on Drug Prices - Public Citizen

In his State of the Union speech, President Trump is expected to tout progress from his administration on lowering drug prices for Americans, but the rhetoric will not match the reality. Here are the ...

011

Reposted by Peter Maybarduk

Public Citizen @publiccitizen.bsky.social · 24/02/2026

People in the U.S. are being charged up to 16x as much as peer countries for the same treatments. This is absurd. As generics manufacturers are expected to begin selling GLP-1s in Canada for less than $100 soon, we're calling on HHS to authorize generic competition for GLP-1 drugs.

05319

Peter Maybarduk @maybarduk.bsky.social · 06/02/2026

TrumpRx is designed to help Big Pharma keep its prices high by diluting the bargaining power of insurance companies, weakening an important check on pharma. Thanks David Lim and Politico for including us

000

Peter Maybarduk @maybarduk.bsky.social · 06/02/2026

Most people will do better through insurance than TrumpRx. Many without insurance will not be able to afford the still-high TrumpRx prices. But drugmakers certainly will appreciate Trump’s free product promos, delivered with a false veneer of price accountability. www.politico.com/news/2026/02...

politico.com

TrumpRx debuts with several dozen discounted drugs

Drug pricing experts have questioned whether the effort would benefit most Americans.

1107

Peter Maybarduk @maybarduk.bsky.social · 03/02/2026

Trump says he lowered drug prices. We’ll believe it when we see it. So we sued for access to the secret deals.

021

Reposted by Peter Maybarduk

Access to Meds | Public Citizen @pcmedsaccess.bsky.social · 26/11/2025

Lenacapavir could sharply cut new HIV infections. But only if people can actually get it. Watch this brief video from @maybarduk.bsky.social on how monopoly power is limiting access, and why World AIDS Day is the moment to demand change. www.instagram.com/p/DRh2CUIjl-Z/

031

Peter Maybarduk @maybarduk.bsky.social · 29/09/2025

High prices start with Big Pharma. Prices won’t fall until we crack down on drug corporations.

010

Peter Maybarduk @maybarduk.bsky.social · 29/09/2025

PhRMA also put figures today to its U.S. infrastructure investments and patient assistance programs. Most of these are not new, and patient assistance programs are notoriously hard to navigate. Lowering prices is a simpler way to promote access to medicine.

110

Peter Maybarduk @maybarduk.bsky.social · 29/09/2025

But the prices are still unaffordably high for most patients and cannot substitute for offering broadly low prices to insurers and benefit managers, to support widespread access.

110

Peter Maybarduk @maybarduk.bsky.social · 29/09/2025

Some drugmakers have announced lower list prices for some drugs through direct-to-patient sales. These can be useful for limited numbers of people.

110

Peter Maybarduk @maybarduk.bsky.social · 29/09/2025

Puffing up direct-to-patient sales lets Big Pharma pass the blame for high prices to insurers and benefit managers, without taking serious responsibility itself to make medicine affordable.

110

Peter Maybarduk @maybarduk.bsky.social · 29/09/2025

Meanwhile, Senator Bernie Sanders (I-Vt.), ranking member of the Senate health committee, issued a report showing that prices are higher now for nearly 700 prescription drugs than when Donald Trump took office. www.sanders.senate.gov/wp-content/u...

110

Peter Maybarduk @maybarduk.bsky.social · 29/09/2025

Today PhRMA announced a new website, AmericasMedicines.com, to support direct-to-patient sales of prescription drugs. The White House had set today as a deadline for drugmakers to offer Americans lower prices or face government action, including an expected rule on most-favored nation pricing.

121

Peter Maybarduk @maybarduk.bsky.social · 29/09/2025

LMAO PhRMA’s long-awaited answer to anger about its prices, which cause rationing & suffering & waste tens of billions in healthcare $$$ is … … a website. To support DTP sales. You would think a trillion-dollar industry that prides itself on innovation could do better. You would be wrong.

110

Reposted by Peter Maybarduk

Public Citizen @publiccitizen.bsky.social · 25/09/2025

Thanks to health leaders Emily Bass, Mitchell Warren, Asia Russell, Amanda Banda, and Isata Dumbuya. And to our event co-hosts UNAIDS, Health GAP, People's Medicines Alliance, UAEM, Treatment Action Group, RESULTS, and Partners In Health.

0226

Reposted by Peter Maybarduk

Public Citizen @publiccitizen.bsky.social · 25/09/2025

We had a critical discussion about continuing the fight to bring medicines to all, with the first step being bringing that breakthrough — at that price — to the world. Thanks to UNAIDS' Winnie Byanyima and Unitaid's Tenu Avafia for joining us today and for your leadership.

1214